The role of clinical response to treatment in determining pathogenicity of genomic variants

Purpose The 2015 American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) guidelines for the interpretation of sequence variants provide a framework to standardize terminology in the classification of variants uncovered through genetic testing. We aimed to assess the validity of utilizing clinical response to therapies specifically targeted to a suspected disease in clarifying variant pathogenicity. Methods Five families with disparate clinical presentations and different genetic diseases evaluated and treated in multiple diagnostic settings are summarized. Results Extended evaluations indicated possible genetic diagnoses and assigned candidate causal variants, but the cumulative clinical, biochemical, and molecular information in each instance was not completely consistent with the identified disease. Initiation of treatment specific to the suspected diagnoses in the affected individuals led to clinical improvement in all five families. Conclusion We propose that the effect of therapies that are specific and targeted to treatable genetic diseases embodies an in vivo physiological response and could be considered as additional criteria within the 2015 ACMG/AMP guidelines in determining genomic variant pathogenicity.

Automated summary

The study assesses the validity of using clinical response to targeted therapies in clarifying the pathogenicity of genetic variants identified through genetic testing. Treatment specific to suspected diagnoses led to clinical improvement in five families with different genetic diseases, suggesting that therapy response could be considered as an additional criterion in determining variant pathogenicity within the existing guidelines.